Observational Study of Lumigan® 0.01% for Treatment of Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Study Identifier
MAF/AGN/OPH/GLA/031
CT.gov Identifier
NCT01568008
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Glaucoma - Open Angle
  • Ocular Hypertension
    • Study Drug
  • Bimatoprost 0.01% ophthalmic solution
    • Phase
    N/A
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Diagnosis of POAG or OHT * Prescribed Lumigan® 0.01%
    Exclusion Criteria:
    * None

    Protocol Summary

    This is an observational study in patients with POAG or OHT that will collect data on the use of Lumigan® 0.01% (bimatoprost 0.01% ophthalmic solution) in a routine clinical setting. Patients will be seen at baseline and at a follow-up visit approximately 8-12 weeks after baseline, as per normal clinical practice.

    Study Locations

    Location
    Status
    Location
    Ghent, Oost-Vlaanderen, Belgium
    Status
    Not applicable